Enoxaparin in the Prevention of Deep Vein Thrombosis in Patients with Acute Ischemic Stroke
Trends in Medical Sciences · 2022
DOI: 10.5812/tms-122415 ↗Kurz gefasst
Fachartikel in der Zeitschrift Trends in Medical Sciences, 2022. Verfasst von Khanh Nguyen Duy und 7 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Thromboseprophylaxe, Schlaganfall
Abstract (Originalsprache)
Background
Deep vein thrombosis (DVT) is a severe complication in patients with acute ischemic stroke. It can cause severe pulmonary embolism, which may result in death. DVT prevalence in ischemic stroke patients ranges from 20 to 70%. Enoxaparin in prophylactic treatment can decrease the risk of developing DVT in patients with acute ischemic stroke. However, optimal enoxaparin dosing for prophylactic treatment in DVT remains elusive. Dosing between 0.3 - 0.5 IU/mL could decrease the prevalence of DVT without increased complications.
Objectives
This study aims to evaluate the benefits and risks of prophylactic treatment in DVT patients with dosing of enoxaparin (Lovenox of Sanofi-Aventis Vietnam Company) 40 mg (4,000 units of anti-Xa, 0.4 mL) once daily.
Methods
Following a cross-sectional design, 58 patients with acute ischemic stroke, who met the inclusion criteria, were studied. Participants received prophylactic treatment of the lower extremities DVT with enoxaparin.
Results
The mean Wells score was 2.14 ± 0.35. Based on the Wells criteria for DVT, all cases had paralysis, muscle weakness, and bedridden recently > 3 days. Also, 4 cases (6.9%) had leg edema; 1 case (1.7%) had superficial collateral veins; 3 cases (5.3%) had previously documented DVT. Thrombocytopenia > 50% after treatment has a non-statistically significant decrease. The 2nd ultrasound showed no case of DVT.
Conclusions
Enoxaparin was not the primary cause of thrombocytopenia in prophylactic treatment. Enoxaparin is a 100% effective means to prevent lower extremity DVT in average-risk patients, and it does not increase the risk of bleeding.
Zitieren
APA
Duy, K. N., Nguyen, D. T., Le, M. V., Le, L. D., Tran, H. C., Kha, N. H., Tran, A. V., & Tran, B. L. T. (2022). Enoxaparin in the Prevention of Deep Vein Thrombosis in Patients with Acute Ischemic Stroke. Trends in Medical Sciences. https://doi.org/10.5812/tms-122415
Vancouver
Duy KN, Nguyen DT, Le MV, Le LD, Tran HC, Kha NH, et al. Enoxaparin in the Prevention of Deep Vein Thrombosis in Patients with Acute Ischemic Stroke. Trends in Medical Sciences. 2022. doi:10.5812/tms-122415
BibTeX
@article{Duy2022,
author = {Duy, Khanh Nguyen and Nguyen, Diem Thi and Le, Minh Van and Le, Long Duy and Tran, Huy Cong and Kha, Nhan Huu and Tran, An Viet and Tran, Bao Lam Thai},
title = {Enoxaparin in the Prevention of Deep Vein Thrombosis in Patients with Acute Ischemic Stroke},
journal = {Trends in Medical Sciences},
year = {2022},
doi = {10.5812/tms-122415}
}
EUVIMED